Ultrasound/Acidity‐Triggered and Nanoparticle‐Enabled Analgesia

Abstract

Local anesthetics have been extensively employed to treat postoperative pain, but they generally suffer from short acting duration and potential neurotoxicity under high local concentrations, which require the controlled and sustained releasing patterns of treatment drugs. In this work, it is reported, for the first time, the construction of hollow mesoporous organosilica nanoparticles (HMONs)‐based nanoplatforms for localized delivery and controlled/sustained release of loaded ropivacaine for local anesthetics, which can be repeatedly triggered by either external ultrasound irradiation or acidity triggering to release the payload, causing on‐demand and long‐lasting analgesia. Based on the in vivo mouse model of incision pain, the controlled and sustained release of ropivacaine achieves more than six hours of continuous analgesia, which is almost three times longer as compared to single free ropivacaine injection. The low neurotoxicity and high biocompatibility of HMONs for nanoparticle‐enabled analgesia are also demonstrated both in vitro and in vivo. This designed/constructed HMONs‐based nanoplatform provides a potential methodology for clinical pain management via on‐demand and long‐lasting pain relief.

Engineering 2D Silicene‐Based Mesoporous Nanomedicine for In Vivo Near‐Infrared‐Triggered Analgesia

“…To further determine the NIR‐triggered releasing pattern of RP from Silicene@MSNs, the UV‐vis spectrophotometer was applied to measure the UV absorbance of RP according to the previously published method. [ 6 ] Using phosphate buffer solution (PBS) as the solvent, RP features a characteristic absorption peak at 263 nm (Figure S3a, Supporting Information). According to the concentration of RP and the UV absorption peak at 263 nm, the calculated standard curve was shown as Figure S3b.…”

“…To address these critical issues, more drug carriers have been rationally built to realize controllable and sustainable drug release [5] with the advancement of nanotechnology. Various forms of nanocarriers such as hollow mesoporous organosilica nanoparticles (HMONs), [6] hydrogels, [7] liposomes, [8] polymeric formulation, [9,10] and metal nanoparticles [11] have been designed, providing a promising strategy to optimize the pharmacokinetic profile of drugs without modifying their chemical structure. We have constructed a nanocarrier based on organic-inorganic hybrid HMONs-based nanoplatforms.…”

“…We have constructed a nanocarrier based on organic-inorganic hybrid HMONs-based nanoplatforms. [12] However, some of the studies need to optimize the controlled release of drugs, and most of them lack the evidence of nerve electrical activity inhibition during analgesia. [13] Above all, it is still highly necessary to further explore the desirable anesthetics with controllable Scheme 1.…”

“…We have constructed a nanocarrier based on organic–inorganic hybrid HMONs‐based nanoplatforms. [ 12 ] However, some of the studies need to optimize the controlled release of drugs, and most of them lack the evidence of nerve electrical activity inhibition during analgesia. [ 13 ] Above all, it is still highly necessary to further explore the desirable anesthetics with controllable and sustainable drug‐releasing performance that can provide adequate analgesia effect for the utilization of local anesthetics generally suffering from short half‐lives and brachychronic local neurotoxicity.…”

Moderate-Intensity Ultrasound-Triggered On-Demand Analgesia Nanoplatforms for Postoperative Pain Management

“…Mice that received injections of DMSN-bupi-PFP combined with ultrasonic irradiation were euthanized on 3 days and 28 days after injection to highlight the potential histocompatibility of DMSN-bupi-PFP in pain management. 43 The sciatic nerve and surrounding muscle tissues were harvested and sectioned for histological analysis. Representative tissue reaction to DMSN-bupi-PFP was evaluated with hematoxylin–eosin (H&E) staining and toluidine blue staining.…”